SGN-CD19A

DRUG2 trials

Sponsors

Seagen Inc.

Conditions

Burkitt LymphomaLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellPrecursor B-cell Lymphoblastic Leukemia-Lymphoma

Phase 1

A Safety Study of SGN-CD19A for B-Cell Lymphoma

CompletedNCT01786135

Seagen Inc.Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse +2

Start: 2013-02-28End: 2017-02-16Updated: 2017-10-19

A Safety Study of SGN-CD19A for Leukemia and Lymphoma

CompletedNCT01786096

Seagen Inc.Burkitt Lymphoma, Precursor B-cell Lymphoblastic Leukemia-Lymphoma

Start: 2013-02-28End: 2017-05-30Updated: 2017-07-02

Related Papers

Abstract 2541: Preclinical results of SGN-CD19A in combination with R-ICE or R-CHOP in non-Hodgkin lymphoma models

Cancer Research2015-08-013 citations

Abstract DDT01-04: SGN-CD19A: A novel Anti-CD19 antibody drug conjugate

Cancer Research2014-10-011 citations

Abstract 4642: Model-based alternative clinical trial designs and evaluations for SGN-CD19A, a novel antibody-drug conjugate

Cancer Research2014-10-01

Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).

Journal of Clinical Oncology2014-05-2012 citations

A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma

Blood2013-11-1515 citations